Telbivudine: A new treatment for chronic hepatitis B

World Journal of Gastroenterology

Volumn 13, Issue 46, 2007, Pages 6150-6155

  Amarapurkar, Deepak N ^a  

^a BOMBAY HOSPITAL   (India)

Author keywords

Adefovir dipivoxil; Antiviral agents; Chronic hepatitis B; Entecavir; Hepatitis B virus; Lamivudine; Nucleoside analogue; Pegylated interferons; Telbivudine

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; DNA POLYMERASE; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2B; PLACEBO; TELBIVUDINE;

AREA UNDER THE CURVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION;

EID: 37849043997     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.13.6150     Document Type: Review

References (31)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745
2. Mohanty SR, Kupfer SS, Khiani V. Treatment of chronic hepatitis B. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 446-458
3. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-1956
4. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-768
5. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156
6. Fung SK, Lok AS. Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 90-97
7. Chowdhury A. Epidemiology of hepatitis B virus infection in India. Hep B Annual 2004; 1: 17-24
8. Thyagrajan SP, Jayaram S, Hari R, Mohan KVK, Murugavel KG. Epidemiology of hepatitis B in India - A comprehensive analysis. In: Hepatitis B and C carrier to cancer. Sarin SK, Okuda K, editors. 1st ed. New Delhi: Harcourt India Private Ltd, 2002: 25-39
9. Tandon BN, Acharya SK, Tandon A. Epidemiology of hepatitis B virus infection in India. Gut 1996; 38 Suppl 2: S56-S59
10. Chowdhury A, Santra A, Pal S, Chakravarty R, Banerji A, Pal S, Dhali GK, Datta S, Banerji S, Manna B, Roy Chowdhury S, Bhattacharya SK, Guha Mazumder D. Community based epidemiological study of Hepatitis B virus infection (HBV). Indian Journal Gastroenterol 2001; 20 Suppl 2: A2
11. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472-489
12. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745
13. Lok AS. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 1992; 10: 46-52
14. Hadziyannis SJ, Bramou T, Alexopoulou A, Makris A. Immunopathogenesis and natural course of anti-HBe positive chronic hepatitis with replicating B virus. In: Hollinger FB, Lemon SM, Margolis HS, editors. Viral Hepatitis and Liver Disease. Baltimore: Williams and Wilkins, 1991: 673-676
15. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31: 1037-1044
16. Miyakawa Y, Okamoto H, Mayumi M. The molecular basis of hepatitis B e antigen (HBeAg)-negative infections. J Viral Hepat 1997; 4:1-8
17. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, Locarnini S. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995; 69: 3350-3357
18. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47: 451-460
19. Jones R, Nelson M. Novel anti-hepatitis B agents: A focus on telbivudine. Int J Clin Pract 2006; 60: 1295-1299
20. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-145
21. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68
22. Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach JL, Hernandez B, Juodawlkis A, Tennant B, Korba B, Cote P, Cretton-Scott E, Schinazi RF, Myers M, Bryant ML, Sommadossi JP. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001; 12 Suppl 1: 119-129
23. Bridges E. Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity, or carcinogenicity [Abstract]. 41st Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria. J Hepatol 2006; 44 (suppl 2): S147
24. Zhou XJ, Lim SG, Lloyd DM, Chao GC, Brown NA, Lai CL. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother 2006; 50: 874-879
25. Zhou XJ, Myers M, Chao GC, Dubuc G, Brown NA. Clinical pharmacokinetics of Telbivudine, a potent antiviral for hepatitis B, in subjects with impaired hepatic or renal function. J Hepatol 2004; 40: (Abstract)
26. Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, Yuen MF, Chao GC, Myers MW. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004; 40: 719-726
27. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-536
28. Lai CL, Gane E, Hsu CW, Thongsawat S, Wang Y, Chen Y. Two year results from the Globe trial in patients with Hepatitis B: Greater clinical and antiviral efficacy for Telbivudine vs lamivudine. Hepatology 2006; 44 Suppl 1: 222A
29. DiBisceglie A, Lai CL, Gane E. Telbivudine GLOBE Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-Year Efficacy in Nucleoside-Treated Hepatitis B Patients. Hepatology 2006; 44 Suppl 1: 230A
30. Hou J, Yin Y, Xu DZ, Tan D, Niu J, Zhou XQ, Wang Y, Zhu L, He Y, Ren H, Win M, Chen C, Wu SM, Chen Y, Xu JZ, Wang Q, Wei L, Chao G, Fielman B, Brown N, Jia JD. A phase III comparative trial of Telbivudine and lamivudine for treatment of chronic hepatitis B in Chinese patients: first year results (Abstract). J Gastroenterol Hepatol 2006; 21 suppl 2: A128-A129
31. Heathcote E, Chan HL, Cho M, Lai C, Moon Y, Chao Y, Myers R, Minuk G, Marcellin P, Jeffers L, Sievert W, Kaiser R, Chao G, Brown N, 018 Study Group. A randomised trial of Telbivudine (LdT) vs adefovir for HBeAg positive chronic hepatitis B: results of the primary week 24 analysis. Gastroenterology 2006; 130 suppl 2: A765 (Abstract)